The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(S)-N-(3,5-difluoro-4-((1s,4s)-4-methylcyclohexyloxy)benzyl)pyrrolidine-2-carboxamide ID: ALA1093698
PubChem CID: 46884137
Max Phase: Preclinical
Molecular Formula: C19H26F2N2O2
Molecular Weight: 352.43
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: C[C@H]1CC[C@@H](Oc2c(F)cc(CNC(=O)[C@@H]3CCCN3)cc2F)CC1
Standard InChI: InChI=1S/C19H26F2N2O2/c1-12-4-6-14(7-5-12)25-18-15(20)9-13(10-16(18)21)11-23-19(24)17-3-2-8-22-17/h9-10,12,14,17,22H,2-8,11H2,1H3,(H,23,24)/t12-,14+,17-/m0/s1
Standard InChI Key: NLCMINSUEGCGSP-QEORTHHSSA-N
Molfile:
RDKit 2D
25 27 0 0 0 0 0 0 0 0999 V2000
-2.2931 -21.0750 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.2943 -21.9023 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5794 -22.3152 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8630 -21.9019 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8659 -21.0713 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5812 -20.6622 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1529 -20.6561 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5631 -21.0659 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.2760 -20.6508 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9917 -21.0606 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2729 -19.8258 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.9700 -21.8849 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7468 -22.1627 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2511 -21.5098 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7859 -20.8285 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.0077 -20.6626 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-3.0091 -22.3143 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-3.7232 -21.9012 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.7186 -21.0766 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.4286 -20.6636 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.1458 -21.0720 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.1485 -21.8980 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.4339 -22.3155 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.8584 -20.6562 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5796 -23.1402 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
6 1 1 0
1 2 2 0
5 7 1 0
12 13 1 0
13 14 1 0
14 15 1 0
15 10 1 0
3 4 2 0
1 16 1 0
7 8 1 0
2 17 1 0
18 17 1 6
18 19 1 0
8 9 1 0
4 5 1 0
10 9 1 1
2 3 1 0
9 11 2 0
18 23 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 1 0
10 12 1 0
21 24 1 6
5 6 2 0
3 25 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 352.43Molecular Weight (Monoisotopic): 352.1962AlogP: 3.29#Rotatable Bonds: 5Polar Surface Area: 50.36Molecular Species: BASEHBA: 3HBD: 2#RO5 Violations: ┄HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 9.80CX LogP: 3.26CX LogD: 0.91Aromatic Rings: 1Heavy Atoms: 25QED Weighted: 0.85Np Likeness Score: -0.49
References 1. Liu KK, Lefker BA, Dombroski MA, Chiang P, Cornelius P, Patterson TA, Zeng Y, Santucci S, Tomlinson E, Gibbons CP, Marala R, Brown JA, Kong JX, Lee E, Werner W, Wenzel Z, Giragossian C, Chen H, Coffey SB.. (2010) Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity., 20 (7): [PMID:20202843 ] [10.1016/j.bmcl.2010.01.107 ]